Cover Image

Short and complex—Telomeres and genomes in CLL

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Billy Michael Chelliah Jebaraj, Stephan Stilgenbauer
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	British Journal of Haematology
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

An AI ‐based IHC quantification technique for assisting in the differentiation of MCL from CLL / SLL
by: Zizhu Tian, et al.
Published: (2026)

Different phenotypes with different endings—Telomere biology disorders and cancer predisposition with long telomeres
by: Sharon A. Savage, et al.
Published: (2024)

Splenectomy and complications: A complex different disease background, yet a common denominator exists
by: Michael D. Diamantidis
Published: (2025)

Optical genome mapping improves detection and characterisation of cytogenetic abnormalities in non‐Hodgkin lymphomas
by: Coura Fall, et al.
Published: (2026)

Chronic eosinophilic leukaemia—Not otherwise specified: Clinical features, genomic insight and therapeutic strategies
by: Alessandro Costa, et al.
Published: (2024)

Integration of genomic and clinical variables improves the prediction of myelodysplastic syndromes to acute myeloid leukaemia transformation and prognosis
by: Huimin Jin, et al.
Published: (2025)

Short‐ and long‐term outcome of neonates with thrombocytopenia from maternal immune thrombocytopenia
by: Boris Sorin, et al.
Published: (2026)

Identification of COQ2 as a regulator of proliferation and lipid peroxidation through genome‐scale CRISPR‐Cas9 screening in myeloma cells
by: Miao Li, et al.
Published: (2024)

Dapsone for paediatric chronic immune thrombocytopenia: Short report from a tertiary centre in South India
by: Niteesh Bharadwaj, et al.
Published: (2024)

Management strategies for patients with chronic lymphocytic leukaemia harbouring complex karyotype
by: Andrea Serafin, et al.
Published: (2025)

Elevated desmoglein‐2 expression in multiple myeloma is a prognostic marker across genomic subtypes with impact on high‐risk cytogenetics and a distinct gene expression profile
by: Barbara J. McClure, et al.
Published: (2026)

Interplay of leucocyte–platelet complexes and clinical response to eltrombopag in immune thrombocytopenia patients
by: Rubén Osuna‐Gómez, et al.
Published: (2024)

Monolobated megakaryocytes and ring sideroblasts: A morphological prelude to multihit TP53 and complex karyotype
by: Javier Marco‐Ayala, et al.
Published: (2025)

Real‐world evidence supports the safety and efficacy profile of luspatercept in clinically complex and heavily iron‐overloaded patients
by: Barbara Gianesin, et al.
Published: (2026)

Beta‐thalassaemia intermedia due to a complex alpha‐globin rearrangement and a heterozygous beta thalassaemia mutation
by: Victor Marin, et al.
Published: (2024)

ET occurring in NPM1 ‐mutated AML during molecular complete remission: A further potential evolution of a complex disease
by: Diego Bertoli, et al.
Published: (2025)

PF4‐associated immune thrombocytopenia and thrombosis (PITT)—More than heparin and vaccines
by: Michael Makris
Published: (2025)

Assessment of intrathecal therapy in the treatment of familial haemophagocytic lymphohistiocytosis
by: Katarina Zivkovic, et al.
Published: (2025)

Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study
by: Klaus Geissler, et al.
Published: (2024)

Multilineage haematopoiesis in the cerebrospinal fluid of an infant
by: Jonas B. Lang, et al.
Published: (2026)

Transforming transfusion practice in the National Health Service to enhance safety, efficiency and clinical outcomes
by: Michael F. Murphy, et al.
Published: (2026)

The Menin story in acute myeloid leukaemia—The road to success
by: Michael W. M. Kühn, et al.
Published: (2024)

Mitigating the impact of blood shortages in England
by: Fateha Chowdhury, et al.
Published: (2024)

Relapse after glofitamab has a poor prognosis and rates of CD20 loss are high
by: Samuel Grigg, et al.
Published: (2024)

Effectiveness of rituximab and biosimilar rituximab in untreated diffuse large B‐cell lymphoma, a Danish population‐based analysis
by: Amal Haujir, et al.
Published: (2025)

Choosing between Nivo ‐ AVD and BrECADD : Hodgkin lymphoma's new era
by: Edward R. Scheffer Cliff, et al.
Published: (2026)

A proposed refined definition of acute myeloid leukaemia patients ineligible for intensive therapy: The Integrated Comorbidity– ECOG –Age criteria
by: Daniel Weidl, et al.
Published: (2026)

Bispecific antibody combination therapies in diffuse large B‐cell lymphoma
by: Sean Harrop, et al.
Published: (2025)

Clinical decision support systems in transfusion
by: Louise H. Strickland, et al.
Published: (2026)

Outcome of T‐cell/histiocyte‐rich large B‐cell lymphoma—A Danish nationwide matched cohort study
by: Peter Brændstrup, et al.
Published: (2025)

Single gene mutations and prognosis in limited‐stage follicular lymphoma treated with radiation therapy
by: Samantha A. Hershenfeld, et al.
Published: (2024)

Understanding variations in the use of tranexamic acid in surgery: A qualitative interview study
by: Louise Strickland, et al.
Published: (2025)

Outcomes of Bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia in US veterans with severe renal dysfunction
by: Chenyu Lin, et al.
Published: (2024)

Real‐world treatment patterns and outcomes among patients with immune thrombocytopenia ( ITP ) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL ‐ AVA 3.5 study
by: Caroline Piatek, et al.
Published: (2026)

Clinical profiles of chronic lymphocytic leukaemia patients with SF3B1 mutations: A single‐institution study
by: Bita Fakhri, et al.
Published: (2025)

Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post‐revumenib therapies
by: Miles Thomas, et al.
Published: (2025)

Major reduction in occurrence of anti‐c and anti‐E in pregnancy after more than 10 years of preventive matched transfusion with most benefit for c‐matching
by: Jessie S. Luken, et al.
Published: (2024)

CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma
by: Emil Arjun Kumar, et al.
Published: (2024)

Can we identify individuals at risk to develop multiple myeloma? A machine learning‐based predictive model
by: Moshe Mittelman, et al.
Published: (2025)

Fetal and neonatal alloimmune thrombocytopenia ( FNAIT ): Survey of UK fetal medicine centres on antenatal management of subsequent affected pregnancies
by: Asha Aggarwal, et al.
Published: (2026)